Influence of early use of sodium-glucose transport protein 2 inhibitors, glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors on the legacy effect of hyperglycemia

• Published in: Frontiers in endocrinology (Lausanne) Vol. 15; p. 1369908
• Main Authors: Deng, Siwei, Zhao, Houyu, Chai, Sanbao, Sun, Yexiang, Shen, Peng, Lin, Hongbo, Zhan, Siyan
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 13.05.2024
• Subjects: Adult; Aged; Blood Glucose - analysis; Blood Glucose - drug effects; Blood Glucose - metabolism; cardiovascular diseases; Cardiovascular Diseases - epidemiology; Diabetes Mellitus, Type 2 - blood; Diabetes Mellitus, Type 2 - drug therapy; Dipeptidyl-Peptidase IV Inhibitors - adverse effects; Dipeptidyl-Peptidase IV Inhibitors - therapeutic use; Endocrinology; Female; Follow-Up Studies; Glucagon-Like Peptide-1 Receptor - agonists; Glycated Hemoglobin - analysis; Glycated Hemoglobin - metabolism; Glycemic Control; Humans; Hyperglycemia - chemically induced; Hyperglycemia - epidemiology; Hypoglycemic Agents - therapeutic use; legacy effect; Male; Middle Aged; novel anti-hyperglycemic agents; population-based cohort; Retrospective Studies; Sodium-Glucose Transporter 2 Inhibitors - therapeutic use; type 2 diabetes mellitus; legacy effect; type 2 diabetes mellitus; cardiovascular diseases; population-based cohort; novel anti-hyperglycemic agents

A phenomenon known as legacy effect was observed that poor glycemic control at early stage of patients with newly-diagnosed type 2 diabetes (T2D) increases the risk of subsequent cardiovascular diseases (CVD). Early use of some novel anti-hyperglycemic agents, such as sodium-glucose transport protei...